TXMD
TherapeuticsMD, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.63 | $2.02 | +24% |
| Renaissance Technologies | Q1 2025(8Q snapshot) | 5Q | $1.03 | $2.02 | +96% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at TherapeuticsMD, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Dec 29, 2025 — the most recent Form 4 on file — not from today.
- Form 40000905148-25-004488Dec 29, 2025
- Form 40000905148-25-003785Nov 5, 2025
- Form 40000905148-25-003784Nov 5, 2025
- Form 40000905148-25-003783Nov 5, 2025
- Form 40000905148-25-003782Nov 5, 2025
- Form 40000905148-25-001216Apr 15, 2025
- Form 40000905148-25-001215Apr 15, 2025
- Form 40000905148-25-001190Apr 10, 2025
- Form 40000905148-25-000740Feb 20, 2025
- Form 40000905148-25-000739Feb 20, 2025
- Form 40000905148-25-000738Feb 20, 2025
- Form 40000905148-25-000737Feb 20, 2025
- Form 40000905148-24-002363Aug 26, 2024
- Form 40000905148-24-002340Aug 23, 2024
- Form 40001209191-23-057725Dec 7, 2023
Fundamentals
XBRL · TherapeuticsMD, Inc.Annual figures sourced directly from TherapeuticsMD, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for TherapeuticsMD, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQUARTERLY REPORTMay 12, 2026
- 8-KCURRENT REPORTMay 12, 2026
- 10-K/AANNUAL REPORTApr 1, 2026
- 8-KCURRENT REPORTMar 30, 2026
- 10-KANNUAL REPORTMar 30, 2026
- 8-KCURRENT REPORTJan 21, 2026
- 8-KCURRENT REPORTDec 16, 2025
- 8-KCURRENT REPORTNov 13, 2025
- 10-QQUARTERLY REPORTNov 12, 2025
- DEF 14APROXY STATEMENTNov 3, 2025
- 10-QQUARTERLY REPORTAug 12, 2025
- 8-KCURRENT REPORTAug 12, 2025
- 10-QQUARTERLY REPORTMay 13, 2025
- 8-KCURRENT REPORTMay 13, 2025
- 10-K/AAMENDMENT NO. 1 TO FORM 10-KApr 30, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | open | $1.96 | $2.02 | +3% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $1.03 | $1.46 | +42% |
| Renaissance Technologies | Q1 2025 | open | $1.03 | $2.02 | +96% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $1.63 | $1.46 | -10% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.